[Federal Register Volume 66, Number 69 (Tuesday, April 10, 2001)]
[Notices]
[Page 18645]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 01-8718]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

[Docket No. 98N-0787]


Parke-Davis Pharmaceutical Research et al.; Withdrawal of 
Approval of 14 New Drug Applications and 13 Abbreviated New Drug 
Applications; Correction

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice; correction.

-----------------------------------------------------------------------

SUMMARY: The Food and Drug Administration (FDA) is correcting a notice 
that appeared in the Federal Register of September 25, 1998 (63 FR 
51359). The document announced the withdrawal of approval of 14 new 
drug applications and 13 abbreviated new drug applications (ANDAs). The 
document inadvertently withdrew approval of ANDA 80-025 for Sulf-10 
(sulfacetamide sodium ophthalmic solution, USP) 10% held by Ciba 
Vision, 11460 Johns Creek Pkwy., Duluth, GA 30097-1556. FDA confirms 
that approval of ANDA 80-025 is still in effect.

EFFECTIVE DATE: September 25, 1998.

FOR FURTHER INFORMATION CONTACT: Olivia A. Pritzlaff, Center for Drug 
Evaluation and Research (HFD-7), Food and Drug Administration, 5600 
Fishers Lane, Rockville, MD 20857, 301-594-2041.
    In FR Doc. 98-25713 appearing on page 51359 in the issue of Friday, 
September 25, 1998, the following correction is made: On page 51360, in 
the table, the entry for ANDA 80-025 is removed.

    Dated: March 26, 2001.
Janet Woodcock,
Director, Center for Drug Evaluation and Research.
[FR Doc. 01-8718 Filed 4-9-01; 8:45 am]
BILLING CODE 4160-01-S